Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

Furthermore, mice treated with a PDGFR-α inhibitor — the anticancer agent, imatinib mesylate — 1 hour following MCAO, had a 33% reduction in cerebrovascular permeability at 24 hours ...

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially ...

The company has also filed an Investigational New Drug (IND) application for a Pro drug formulation of imatinib mesylate for PAH, with clinical development set to begin later this year.

In 2003, Natco Pharma launched its Oncology division with introduction of flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia. In 2006, Natco Pharma ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...